Vaccination Prior To COVID-19 Infection Provided 60% Protection Against Post-Discharge Mortality: ICMR Research Study

New Delhi : The study on factors related to the post-discharge one-year mortality among hospitalized COVID-19 patients study conducted by the Indian Council of Medical Research (ICMR) has revealed that vaccination prior to the COVID-19 infection (at least a single dose) provided 60 percent protection against post-discharge mortality. The study read,

“The study found a higher chance of dying within one year after discharge in males, those more than 40 years of age, those with comorbidities and those who had moderate-severe COVID disease to begin with. Vaccination prior to the COVID-19 infection (at least a single dose) provided 60% protection against post-discharge mortality. Similar trends were seen in participants, 18-45 years of age.”

It is worth mentioning that these results relate to patients who had been hospitalized during their initial COVID-19 infection and cannot be generalized to all COVID-19 patients.

The study conducted by the National Clinical Registry for Covid-19 team has evaluated the factors related to one-year post-discharge mortality. It said,

“National Clinical Registry for COVID-19 study team has conducted nested matched case-control analyses to evaluate the factors related to one-year post-discharge mortality.”

ICMR has been maintaining the National Clinical Registry for COVID-19 at 31 centres across the country, where all hospitalized COVID-19 patients were periodically contacted by telephone till one year after discharge. Data collected till February 2023 were included in this analysis.

According to the study,

“It was observed that of the 14,419 participants contacted at least once in one year after discharge from hospital, 942 (6.5%) all-cause mortality was reported. A nested matched case-control analysis was conducted to evaluate the factors related to one-year post-discharge mortality.”

ICMR is conducting more such studies like the Effect of the COVID-19 vaccine on thrombotic (blood clot within the blood vessels restricting the flow of blood) events among the 18–45-year-old population in India, 2022, said the Multicentric hospital-based matched case-control study.

Related Posts

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

Gleneagles BGS Hospital, Kengeri, Bengaluru, part of the Fortis Healthcare Network, marked World Organ Donation Day with its annual commemorative event, ‘A Legacy That Lives On.’ The event brought together…

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

Punjab: The Narcotics Control Bureau (NCB) has uncovered an alleged pharmaceutical-drug diversion network operating through rural areas of Punjab. Investigators are tracing the movement of fentanyl and other drugs regulated…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

Bombay HC tells Maharashtra FDA to be ‘judicious’ after Cadila challenges order to ban sale of some medicines

Bombay HC tells Maharashtra FDA to be ‘judicious’ after Cadila challenges order to ban sale of some medicines

‘Erring pharma companies’: Over 1,000 cough syrup manufacturers undergo intense audits

‘Erring pharma companies’: Over 1,000 cough syrup manufacturers undergo intense audits

Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses

Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses